Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
2.
Cancer Res ; 67(13): 6092-9, 2007 Jul 01.
Article in English | MEDLINE | ID: mdl-17616664

ABSTRACT

We investigated the role of microRNAs (miRNAs) in the pathogenesis of human hepatocellular carcinoma (HCC). A genome-wide miRNA microarray was used to identify differentially expressed miRNAs in HCCs arisen on cirrhotic livers. Thirty-five miRNAs were identified. Several of these miRNAs were previously found deregulated in other human cancers, such as members of the let-7 family, mir-221, and mir-145. In addition, the hepato-specific miR-122a was found down-regulated in approximately 70% of HCCs and in all HCC-derived cell lines. Microarray data for let-7a, mir-221, and mir-122a were validated by Northern blot and real-time PCR analysis. Understanding the contribution of deregulated miRNAs to cancer requires the identification of gene targets. Here, we show that miR-122a can modulate cyclin G1 expression in HCC-derived cell lines and an inverse correlation between miR-122a and cyclin G1 expression exists in primary liver carcinomas. These results indicate that cyclin G1 is a target of miR-122a and expand our knowledge of the molecular alterations involved in HCC pathogenesis and of the role of miRNAs in human cancer.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Cyclins/metabolism , Gene Expression Regulation, Neoplastic , Liver Neoplasms/metabolism , MicroRNAs/metabolism , RNA, Neoplasm/genetics , Carcinoma, Hepatocellular/virology , Cell Line, Tumor , Cyclin G , Cyclin G1 , Female , Gene Expression Profiling , Hepacivirus/metabolism , Humans , Liver Neoplasms/virology , Male , MicroRNAs/biosynthesis , MicroRNAs/genetics , Transfection
3.
Ther Drug Monit ; 27(6): 816-8, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16306860

ABSTRACT

A 64-year-old man on chronic hemodialysis for end-stage renal disease developed peritoneal carcinomatosis, and palliative chemotherapy with fluorouracil was started. The drug was administered (325 mg/m as IV bolus, at 2 PM) on 2 separate occasions, ie, 1 hour after dialysis and 2 days later, 49 hours after dialysis. The time course of the fluorouracil plasma concentration was determined, and the main pharmacokinetic parameters were calculated. The slope of the monoexponential decay of plasma concentration was significantly greater 1 hour (0.161 minutes) than 49 hours after dialysis (0.127 minutes), and plasma clearance was correspondingly higher (1.78 L/min versus 1.46 L/min). The volume of distribution did not change (11.1 L versus 11.5 L). Because fluorouracil is minimally excreted by the renal route (about 10% of the dose) and is almost entirely metabolized by dihydropyrimidine dehydrogenase (DPD), it is suggested that plasma factors that accumulate during the interdialytic period and are removed by dialysis may inhibit DPD activity and, consequently, fluorouracil metabolic clearance.


Subject(s)
Fluorouracil/pharmacokinetics , Kidney Failure, Chronic/therapy , Renal Dialysis , Antimetabolites, Antineoplastic/pharmacokinetics , Antimetabolites, Antineoplastic/therapeutic use , Fluorouracil/therapeutic use , Humans , Injections, Intravenous , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/metabolism , Male , Metabolic Clearance Rate , Middle Aged , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/etiology , Peritoneal Neoplasms/metabolism
4.
Int J Oncol ; 25(6): 1781-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15547717

ABSTRACT

Adrenomedullin (AM) is a hypotensive peptide, that acts via the calcitonin receptor-like receptor (CRLR), whose interaction with the subtypes 2 and 3 of a family of receptor activity-modifying proteins (RAMP) gives rise to two distinct AM receptors, named AM1 and AM2 receptors. AM derives from the post-translational proteolytic cleavage of pro(p)AM, the last step of which involves the conversion of the inactive AM to active AM by the peptidyl-glycine alpha-amidating monooxigenase (PAM). Compelling evidence suggests that AM, in addition to exerting its well-known regulatory action on blood pressure and water and electrolyte balance, also possesses a growth promoting effect in several normal and neoplastic tissues, including human prostate. Conventional reverse transcription (RT)-polymerase chain reaction (PCR) demonstrated the expression of pAM, PAM, CRLR and RAMP(1-3) mRNAs in both prostate hyperplasias (PH) and carcinomas (PC), and semiquantitative PCR showed that pAM, PAM and RAMP3 mRNA expression was higher in PCs than PHs. Radioimmunoassay measured higher concentrations of immunoreactive AM in PCs than PHs. The expression of pAM, CRLR and RAMP1,2 mRNAs was also detected in the PC-derived cell lines PC-3 and DU-145, RAMP3 expression being restricted to the latter line. AM did not affect the growth rate (duplication time) of PC-3 cells, but it did significantly increase that of DU-145 cells. The growth promoting effect of AM was found to ensue from both the rise in the proliferation rate and the lowering in the apoptosis rate of DU-145 cells. These effects of AM were counteracted by the AM receptor antagonists CGRP(8-37) and AM(22-52), the former antagonist, which is more selective for AM2 than AM1 receptors, being more effective than the latter one. Both antagonists were per se able to induce a slow, but significant decrease in the basal growth rate of DU-145 cells by inhibiting proliferation and enhancing apoptosis, again CGRP(8-37) being more effective than AM(22-52). Taken together, our findings allow us to suggest that: i) endogenous AM system plays an important autocrine-paracrine growth promoting action in the human prostate, being possibly involved in the development of the malignant phenotype of epithelial cells; and ii) the tumor promoting effect of AM in the human prostate is mainly mediated by the AM2 receptor (CRLR/RAMP3) subtype.


Subject(s)
Gene Expression Profiling , Peptides/pharmacology , Peptides/physiology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Receptors, Peptide/biosynthesis , Adrenomedullin , Apoptosis , Cell Proliferation , Cell Transformation, Neoplastic , Humans , Male , Phenotype , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Radioimmunoassay , Receptors, Adrenomedullin , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation
5.
Cancer Res ; 64(22): 8156-9, 2004 Nov 15.
Article in English | MEDLINE | ID: mdl-15548679

ABSTRACT

Gene promoter methylation causes loss of tumor suppressor genes function in human cancer. Here, we show that the CDH4 gene, a member of the cadherin family encoding for R-cadherin, contains a CpG island located at the 5' of the first exon, which functions as a promoter element and is frequently affected by methylation in human cancer. By using methylation-specific PCR and reverse transcription-PCR in human cancer cell lines, promoter methylation could be directly linked to loss of gene expression. After treatment with the demethylating agent 5-aza-2-deoxycytidine, expression could be restored. Analysis of human primary tumors revealed that the CDH4 gene is methylated in 78% (38 of 49) of colorectal and 95% (20 of 21) of gastric carcinomas. CDH4 methylation was not detected in nonneoplastic colonic (0 of 10) and stomach (0 of 10) tissues or in peripheral blood (0 of 17). CDH4 methylation was detected in histologically normal tissues located in proximity of the neoplasms, indicating that CDH4 methylation is an early event in gastrointestinal tumor progression. We also proved that CDH4 methylation can be revealed in the peripheral blood of cancer patients. Our results indicate that CDH4 may act as a tumor suppressor gene in human gastrointestinal tumors and can potentially be used as an early diagnostic marker for gastrointestinal tumorigenesis.


Subject(s)
Colorectal Neoplasms/genetics , DNA Methylation , Promoter Regions, Genetic , Stomach Neoplasms/genetics , Base Sequence , DNA Primers , Humans , Reverse Transcriptase Polymerase Chain Reaction
6.
Genes Chromosomes Cancer ; 41(4): 395-9, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15382262

ABSTRACT

We performed cytogenetic and molecular studies on an adult patient with refractory anemia with an excess of blasts with an add(11)(p15). Multicolor fluorescence in situ hybridization (FISH) identified the extra material on 11p as belonging to chromosome 15. Metaphase FISH with probes for chromosomes 5, 11, and 15 revealed a complex four-break rearrangement. Clone RP5-1173K1, containing exons 10-20 of the NUP98 gene, gave three fluorescence signals on the normal 11, the der(5), and the der(15). 3'-RACE-PCR identified an in-frame fusion between NUP98 and NSD1, which was confirmed by RT-PCR. Two different spliced forms, that is, NUP98 exon 11/NSD1 exon 6 and NUP98 exon 12/NSD1 exon 6, were detected. The reciprocal NSD1/NUP98 was not found. A dual-color experiment with RP5-1173K1 and CTC-549A4, spanning the entire NSD1 gene, indicated an insertion of NUP98 into the NSD1 locus. This is the first report of an adult with myelodysplastic syndrome (MDS) harboring an NUP98/NSD1 fusion resulting from insertion of 5'-NUP98 into the NSD1/5q35 locus.


Subject(s)
Anemia, Refractory/genetics , Intracellular Signaling Peptides and Proteins/genetics , Nuclear Pore Complex Proteins/genetics , Nuclear Proteins/genetics , Amino Acid Sequence , Anemia, Refractory/pathology , Base Sequence , Chromosome Breakage , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 15 , Chromosomes, Human, Pair 5 , Exons , Histone Methyltransferases , Histone-Lysine N-Methyltransferase , Humans , In Situ Hybridization, Fluorescence , Male , Middle Aged , Molecular Sequence Data , Translocation, Genetic
7.
J Hematother Stem Cell Res ; 12(4): 425-34, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12965079

ABSTRACT

To investigate the mechanisms of mobilization and of the factors implicated in the homing of progenitors and possibly understand the reasons for unpredicted mobilization failure, we analyzed CXCR-4 (CD184) expression on bone marrow (BM) CD34+ cells prior to peripheral blood stem cell (PBSC) mobilization in 24 patients affected by hematologic malignancies (non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia). We wanted to determine whether the level of CXCR-4 expressed by hematopoietic stem cells could influence mobilization process and therefore could be considered a predictive factor for mobilization adequacy. These data were also compared with stromal cell function as assessed by colony forming unit-fibroblast (CFU-F) and CFU endothelial cells (CFU-En) assays and stromal layer confluence capacity exhibited by patients' BM cells. In this study, we also compared CXCR-4 expression on CD34+ cells from different sources and at different migration stages specifically bone marrow (BM), steady state peripheral blood (SSPB), fetal cord blood (FCB), cord blood (CB), and mobilized PBSC. Seven (29%) of the 24 patients undergoing mobilization failed to achieve an adequate number of CD34+ stem cells (5 x 10(6)/kg CD34+ cells) and showed a very high expression frequency of CXCR-4 on BM CD34(+) stem cells (mean number of positive cells, 97%) investigated before the mobilization regimen. We also found that high expression intensity per cell for CXCR-4 was associated with lower amounts of mobilized CD34+ cells whereas those patients (17 out of 24 patients, 71%) with lower expression intensity per cell of CD184 on BM CD34+ cells prior to mobilization harvested at least 5 x 10(6)/kg CD34+ cells. Setting a cut off of 5 x 10(6)/kg CD34+ cells harvested, patients mobilizing less had a mean value of 97% CD34+ cells expressing CXCR-4 with a relative mean channel fluorescence of 458 whereas patients mobilizing more than 5 x 10(6)/kg CD34+ progenitors showed a mean value of 59.8% CD34+/CXCR4+ cells with a relative mean channel fluorescence value of 305. Interestingly, in the poor mobilizers group, the marrow stromal microenvironment was found to be more severely damaged in comparison with that of good mobilizers. The comparative analysis of CXCR-4 expression showed no difference in percentage values between steady-state PB (87.4%) and BM (85.1%) stem cells whereas mobilized CD34+ stem cells have a lower expression frequency of CXCR-4 (71.6%) compared to that of progenitors from other sources. Fetal blood CD34+ stem cells had the lowest mean expression frequency of CD184 antigen (36.3%), while CB cells had the highest (94.8%). In conclusion, this study provides evidence that monitoring CXCR-4 CD34 double positive cells before mobilization can be regarded as a predictive factor for mobilization outcome, giving us directional cues for the choice of the best stem cell mobilization regimens.


Subject(s)
Antigens, CD34/biosynthesis , Bone Marrow Cells/metabolism , Hematologic Neoplasms/blood , Receptors, CXCR4/biosynthesis , Bone Marrow Cells/cytology , Cell Movement , Erythroid Precursor Cells , Fetal Blood/cytology , Fibroblasts/metabolism , Flow Cytometry , Hematologic Neoplasms/therapy , Hematopoietic Stem Cells/cytology , Humans , Leukapheresis , Middle Aged , Peripheral Blood Stem Cell Transplantation/methods , Stem Cells , Time Factors
8.
Nutrition ; 19(6): 510-4, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12781850

ABSTRACT

OBJECTIVE: Bioelectrical impedance vector analysis allows non-invasive evaluation of soft tissue hydration and mass through pattern analysis of vector plots as height, normalized resistance, and reactance measurements. METHODS: Whole-body impedance measurements were made with a single frequency (50 kHz) analyzer (BIA-101, Akern/RJL Systems) in 148 adult, white, male subjects 45 to 85 y old: 56 healthy control subjects, 31 cancer patients after surgical procedure (without disease), and 61 patients with locally advanced (30 patients) or disseminated (31 patients) disease with the same body mass index and age. All patients were free from antineoplastic treatment and active nutritional intervention. RESULTS: Mean vectors of cancer groups without disease and locally advance disease versus the control group were characterized by a comparable normalized resistance component with a reduced reactance component (separate 95% confidence limits, P < 0.05), indicating a comparable ionic conduction (hydration) with loss of dielectric mass (cell membranes and tissue interfaces) of soft tissues. Overlapping 95% confidence limits of their mean vectors indicated comparable electrical tissue properties in less versus more advanced disease. CONCLUSION: Monitoring vector displacement trajectory toward the reference target vector position may represent useful feedback in support therapy planning of individual patients.


Subject(s)
Body Composition , Electric Impedance , Neoplasms/complications , Neoplasms/physiopathology , Aged , Aged, 80 and over , Body Mass Index , Cachexia/etiology , Cachexia/physiopathology , Esophageal Neoplasms/complications , Esophageal Neoplasms/physiopathology , Gastrointestinal Neoplasms/complications , Gastrointestinal Neoplasms/physiopathology , Humans , Lung Neoplasms/complications , Lung Neoplasms/physiopathology , Middle Aged
9.
Mol Diagn ; 7(3-4): 201-7, 2003.
Article in English | MEDLINE | ID: mdl-15068392

ABSTRACT

BACKGROUND: Gene promoter methylation is a mechanism for tumor suppressor gene silencing and inactivation. The development of highly sensitive methods for revealing aberrant cancer-associated DNA methylation allows the identification of tumor markers not only in tumor samples, but also in body fluid, an approach that can be useful in the early detection of neoplasms. METHODS: We analyzed the methylation status at 16 loci in tumor samples of the gastrointestinal tract and in early or pre-neoplastic lesions of the colon. RESULTS: Tumor samples revealed that methylation at the transmembrane protein containing epidermal growth factor and follistatin domains (TPEF) locus had the best ratio of discrimination between tumor samples versus normal tissues (83 versus 0%). Its combination with hypermethylated in cancer 1 (HIC1), death-associated protein kinase (DAPK) and O-6-methylguanine DNA methyltransferase (MGMT), allowed the detection of aberrant methylation in 98% of colorectal carcinomas and 100% of gastric carcinomas. The same alterations were also detected in colon adenomas and tissues surrounding the adenomas, indicating that hypermethylation at these loci occurred early in tumor progression. Analysis of DNA from peripheral blood revealed that TPEF methylation was detectable in colorectal tumor patients and patients with early or pre-neoplastic lesions, but not in healthy volunteers. CONCLUSIONS: Our results identify TPEF as a tumor marker that could be useful in the follow-up of gastrointestinal cancer patients or the screening of individuals at risk of developing gastrointestinal neoplasms.


Subject(s)
DNA Methylation , DNA, Neoplasm/genetics , Gastrointestinal Neoplasms/genetics , Multigene Family/genetics , Adenoma/genetics , Colonic Neoplasms/genetics , DNA, Neoplasm/blood , DNA, Neoplasm/isolation & purification , Humans , Promoter Regions, Genetic/genetics , Stomach Neoplasms/genetics
10.
Br J Clin Pharmacol ; 54(2): 131-9, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12207632

ABSTRACT

AIMS: To verify whether fluorouracil (FU) clearance (CL) and volume of distribution (V(ss)) are better correlated with specific body compartments, such as body cell mass (BCM), total body water (TBW) or fat free mass (FFM), rather than with body surface area (BSA) or total body weight (BW). METHODS: Thirty-four patients (13 females and 21 males) affected by colorectal cancer and receiving FU as adjuvant therapy entered the study. CL and Vss were determined after a 2 min i.v. injection of FU (425 mg m(-2)) and leucovorin (20 mg m(-2)). Body composition, in terms of BCM, TBW and FFM, was evaluated non-invasively by bioelectrical impedance analysis (BIA). RESULTS: Significant but poor correlations were found between CL or V(ss) and most anthropometric parameters, including BIA-derived measures (r2 range=0.10-0.21). However, when multiple regression analysis was performed with sex, TBW and FFM as independent variables, the correlations improved greatly. The best correlation was obtained between CL and sex (r2=0.44) and between V(ss) and sex (r2=0.36). FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females. Surprisingly, V(ss) was highly correlated with CL (r2=0.67; CL=0.52+V(ss) x 0.040). This finding may either be explained by extensive drug metabolism in extra-hepatic organs or by variable inactivation on first-pass through the lung. Both these hypotheses need experimental validation. CONCLUSIONS: The pharmacokinetics of FU are better predicted by FFM and TBW than by standard anthropometric parameters and predictions are sex-dependent. The use of BIA may lead to improved dosing with FU.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Body Composition/physiology , Body Water/metabolism , Fluorouracil/pharmacokinetics , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/therapeutic use , Body Surface Area , Body Weight/physiology , Colorectal Neoplasms/drug therapy , Electric Impedance , Female , Fluorouracil/therapeutic use , Humans , Leucovorin/therapeutic use , Male , Middle Aged , Predictive Value of Tests , Sex Factors
11.
Cancer ; 95(3): 569-75, 2002 Aug 01.
Article in English | MEDLINE | ID: mdl-12209749

ABSTRACT

PURPOSE: To evaluate the efficacy and side effects of psolaren with ultraviolet light A (PUVA) and interferon-alpha-2a (IFN-alpha-2a) in patients with mycosis fungoides (MF) and Sézary syndrome (SS). PATIENTS AND METHODS: From May 1993 to January 1999, 63 symptomatic patients with all stages of MF and SS were treated in a prospective Phase II trial with systemic escalating doses of IFN-alpha-2a combined with PUVA for 1 year, followed by indefinite PUVA maintenance in complete responding patients. RESULTS: Sixty-three patients were enrolled (Stage IA, n = 6; IB, n = 37; IIA, n = 3; IIB, n = 3; III, n = 12; IVA, n = 2). Ten patients had received previous therapy. The median follow-up duration for the entire cohort is 37 months. Of 63 patients, 51 achieved a complete response (CR; 74.6%) or partial response (PR; 6%) to therapy. The median response duration is 32 months. The 5-year overall survival rate is 91% and the 5-year disease-free survival rate is 75%. No life-threatening side effects were observed. Five patients stopped IFN-alpha-2a therapy due to toxicity. Eighty-four percent of the patients received more than 75% of the planned dose (12 million units three times a week). CONCLUSIONS: This combination of IFN-alpha-2a and phototherapy is an effective and safe therapy for patients with symptomatic MF.


Subject(s)
Antineoplastic Agents/therapeutic use , Interferon-alpha/therapeutic use , Lymphoma, T-Cell, Cutaneous/drug therapy , PUVA Therapy , Skin Neoplasms/drug therapy , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Interferon alpha-2 , Lymphoma, T-Cell, Cutaneous/pathology , Male , Recombinant Proteins , Skin Neoplasms/pathology , Time Factors , Treatment Outcome
12.
Ther Drug Monit ; 24(3): 425-31, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12021636

ABSTRACT

All limited sampling models so far proposed to determine the area under the concentration-time curve (AUC) of anticancer drugs can be applied only to the dosing/sampling schedule used to obtain the model. The authors have developed a new method to predict the AUC of 5-fluorouracil (5-FU) after rapid intravenous bolus administration of various doses, using as few as two plasma drug concentrations. The 5-FU AUC (AUC(true)) was first determined in 20 patients receiving adjuvant therapy for colorectal cancer, based on nine plasma drug concentrations obtained at 0, 2.5, 5, 10, 15, 20, 30, 45, and 60 minutes after drug administration. Ten patients received 375 mg/m(2) 5F-U + 100 mg/m(2) leucovorin and 10 received 425 mg/m(2) 5-FU + 20 mg/m(2) leucovorin. The kinetics of 5-FU was described by either a one- or two-compartment linear model, as needed. The AUC was then recalculated (AUC(approx)) using a reduced number of plasma concentrations and a simple one-compartment model. The time combinations tested were 2.5, 5, 10, and 20; 2.5, 10, and 20; 5, 10, and 20; 5 and 20; and 2.5 and 20 minutes. The accuracy and precision of the method in predicting the AUC(true) were measured by calculating the mean prediction error (MPE%) and the mean absolute error (MAE%) of the AUC(approx). MPE% ranged between -0.8% and -8.3% and MAE% between 6.1% and 9.5%, depending on the time combination used. In general, all limited sampling models tested tended to underestimate the AUC(true) slightly, particularly when 5-FU kinetics followed a two-compartment model, but bias was still within acceptable limits. The best results were obtained with plasma concentrations measured at 2.5 and 20 minutes after drug bolus (MPE%, -0.8%; MAE%, 6.1%). Although 5-FU kinetics was dose-dependent, MPE% and MAE% were not significantly different between the two groups. These data show that 5-FU AUC can be reliably predicted by using just two plasma concentrations and a one-compartment model, even when different doses are used and plasma concentration decay is biexponential.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Fluorouracil/pharmacokinetics , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/blood , Area Under Curve , Female , Fluorouracil/administration & dosage , Fluorouracil/blood , Humans , Infusions, Intravenous , Male , Middle Aged , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...